Linoleate acetate (MOL008 OB = 42.10%, DL = 0.20, HL = 7.48) is used in the treatment of NSCLC to inhibit inflammatory factors COX, LOX and TNF-α in the TME, which were closely related to their immune activities [30, 31]. Here, LOX is linked to non-small cell lung carcinoma.